Abstract
HGF is a mesenchyme-derived pleiotropic factor, which regulates cell growth, cell motility, and morphogenesis of various types of cells and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis. Although HGF was originally identified as a potent mitogen for hepatocytes, it has also been identified as a member of angiogenic growth factors. Interestingly, the presence of its specific receptor, c-met, is observed in vascular cells and cardiac myocytes. In addition, among growth factors, the mitogenic action of HGF on human endothelial cells was most potent. Recent studies have demonstrated the potential application of HGF to treat cardiovascular diseases such as peripheral vascular disease, myocardial infarction and cerebrovascular disease. In this review, we will discuss a potential therapeutic strategy using HGF in cardiovascular disease.
Keywords: angiogenesis, restenosis, gene therapy, peripheral vascular disease, myocardial infarction
Current Gene Therapy
Title: Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Volume: 4 Issue: 2
Author(s): Ryuichi Morishita, Motokuni Aoki, Naotaka Hashiya, Keita Yamasaki, Hitomi Kurinami, Shiro Shimizu, Hirofumi Makino, Yasushi Takesya, Junya Azuma and Toshio Ogihara
Affiliation:
Keywords: angiogenesis, restenosis, gene therapy, peripheral vascular disease, myocardial infarction
Abstract: HGF is a mesenchyme-derived pleiotropic factor, which regulates cell growth, cell motility, and morphogenesis of various types of cells and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis. Although HGF was originally identified as a potent mitogen for hepatocytes, it has also been identified as a member of angiogenic growth factors. Interestingly, the presence of its specific receptor, c-met, is observed in vascular cells and cardiac myocytes. In addition, among growth factors, the mitogenic action of HGF on human endothelial cells was most potent. Recent studies have demonstrated the potential application of HGF to treat cardiovascular diseases such as peripheral vascular disease, myocardial infarction and cerebrovascular disease. In this review, we will discuss a potential therapeutic strategy using HGF in cardiovascular disease.
Export Options
About this article
Cite this article as:
Morishita Ryuichi, Aoki Motokuni, Hashiya Naotaka, Yamasaki Keita, Kurinami Hitomi, Shimizu Shiro, Makino Hirofumi, Takesya Yasushi, Azuma Junya and Ogihara Toshio, Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF), Current Gene Therapy 2004; 4 (2) . https://dx.doi.org/10.2174/1566523043346453
DOI https://dx.doi.org/10.2174/1566523043346453 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Risk in Postmenopausal Women with Polycystic Ovary Syndrome
Current Vascular Pharmacology HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview
Current Drug Metabolism Editorial [Hot Topic: Novel Peptides and Proteins in Diabetes Mellitus (Guest Editors: Po Sing Leung and Marc de Gasparo)]
Current Protein & Peptide Science DNA and RNA Aptamers as Modulators of Protein Function
Medicinal Chemistry Clinical Presentation, Diagnostic Work-Up, and Treatment of Coronary In-Stent Restenosis
Vascular Disease Prevention (Discontinued) The Renin-Angiotensin Systems: Evolving Pharmacological Perspectives for Cerebroprotection
Current Pharmaceutical Design Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism
Vascular Disease Prevention (Discontinued) Healthcare Utilization, Unmet Service Needs, and Medication Adherence Among People Living with HIV/AIDS
Current HIV Research Prostacyclin Analogues: Prevention of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Imaging with Nucleic Acid Aptamers
Current Medicinal Chemistry Hypertension in Egypt: A Systematic Review
Current Hypertension Reviews Endothelial Dysfunction in Hyperglycemia as a Trigger of Atherosclerosis
Current Diabetes Reviews SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry BHUx: A Patented Polyherbal Formulation to Prevent Hyperlipidemia and Atherosclerosis
Recent Patents on Inflammation & Allergy Drug Discovery Metabolic Syndrome as a Modifier of Atherosclerosis in Murine Models
Current Drug Targets Current Status of CETP Inhibitors in the Treatment of Hyperlipidemia: An Update
Current Clinical Pharmacology Inflammasome Signaling and Other Factors Implicated in Atherosclerosis Development and Progression
Current Pharmaceutical Design Surgery for Severe Obesity: Indications, Techniques, Mechanisms of Weight Loss and Diabetes Resolution
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Ferric Cycle Activity and Alzheimer Disease
Current Neurovascular Research Clinical Consequences and Novel Therapy of Hyperphosphatemia: Lanthanum Carbonate for Dialysis Patients
Recent Patents on Cardiovascular Drug Discovery